Ocugen's OCU410 Phase 1/2 Trial Shows Promising Results in Treating Eye Disease
Friday, 5 April 2024, 14:56
Ocugen Advances Phase 1/2 Trial for Eye Disease Candidate
Ocugen's intensifies efforts to address eye diseases.
Key Highlights:
- Phase 1/2 trial for gene therapy candidate OCU410
- Positive signs of tolerability in treating geographic atrophy
Investors react positively to the advancements, showing confidence in potential breakthroughs in gene therapy treatments.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.